KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Operating Expenses: 2019-2024

Historic Operating Expenses for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to $537.8 million.

  • Recursion Pharmaceuticals' Operating Expenses rose 42.54% to $177.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $767.3 million, marking a year-over-year increase of 67.03%. This contributed to the annual value of $537.8 million for FY2024, which is 36.29% up from last year.
  • Recursion Pharmaceuticals' Operating Expenses amounted to $537.8 million in FY2024, which was up 36.29% from $394.6 million recorded in FY2023.
  • Over the past 5 years, Recursion Pharmaceuticals' Operating Expenses peaked at $537.8 million during FY2024, and registered a low of $88.6 million during FY2020.
  • In the last 3 years, Recursion Pharmaceuticals' Operating Expenses had a median value of $394.6 million in 2023 and averaged $406.0 million.
  • Data for Recursion Pharmaceuticals' Operating Expenses shows a peak YoY surged of 117.84% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Recursion Pharmaceuticals' Operating Expenses stood at $88.6 million in 2020, then spiked by 117.84% to $193.0 million in 2021, then surged by 48.00% to $285.6 million in 2022, then soared by 38.19% to $394.6 million in 2023, then spiked by 36.29% to $537.8 million in 2024.